OTC Markets EXMKT - Delayed Quote USD

MultiCell Technologies, Inc. (MCET)

Compare
0.0000 0.0000 (0.00%)
At close: October 18 at 4:00 PM EDT
Loading Chart for MCET
DELL
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0001
  • Volume 20,000
  • Avg. Volume 0
  • Market Cap (intraday) 1M
  • Beta (5Y Monthly) -37.22
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

2

Full Time Employees

November 30

Fiscal Year Ends

Recent News: MCET

View More

Performance Overview: MCET

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MCET
90.00%
S&P 500
22.95%

1-Year Return

MCET
90.00%
S&P 500
34.10%

3-Year Return

MCET
90.00%
S&P 500
31.16%

5-Year Return

MCET
90.00%
S&P 500
95.62%

Compare To: MCET

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MCET

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.49%

  • Return on Assets (ttm)

    -136.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    805.24k

  • Net Income Avi to Common (ttm)

    -253.6k

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    281.12k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -179.9k

Research Analysis: MCET

View More

Company Insights: MCET

Research Reports: MCET

View More

People Also Watch